Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies

Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies

Detalles Bibliográficos
Autores principales:	van Griensven, J, Edwards, T, Baize, S, Ebola-Tx Consortium, Horby, P
Formato:	Journal article
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2016

Ejemplares similares

Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay
por: Emma M. Bentley, et al.
Publicado: (2021-08-01)

Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration
por: Wesley V Cain, et al.
Publicado: (2022-01-01)

Symptom-Based Ebola Risk Score for Ebola Virus Disease, Conakry, Guinea
por: Brecht Ingelbeen, et al.
Publicado: (2018-06-01)

Ebola virus antibody decay–stimulation in a high proportion of survivors
por: Adaken, C, et al.
Publicado: (2021)

Studies of Ebola Virus persistence in the Body Fluids of a Patient at Advanced Stages of Convalescence
por: A. A. Lopatin, et al.
Publicado: (2015-09-01)

Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola
por: Shan Lu
Publicado: (2014-01-01)

Analysis of related factors of plasma antibody titer in convalescent patients with COVID-19
por: Xin HU, et al.
Publicado: (2023-09-01)

Persistent intraocular Ebola virus RNA is associated with severe uveitis in a convalescent rhesus monkey
por: Gabriella Worwa, et al.
Publicado: (2022-11-01)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
por: Maurice Steenhuis, et al.
Publicado: (2021-01-01)

Towards characterized convalescent plasma for COVID-19: The dose matters
por: Hans P. Verkerke, et al.
Publicado: (2020-09-01)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Daniele Focosi, et al.
Publicado: (2022-05-01)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Gil C. De Santis, et al.
Publicado: (2022-03-01)

Convalescent plasma for administration of passive antibodies against viral agents
por: Giovanni Di Minno, et al.
Publicado: (2020-12-01)

Efficacy of convalescent plasma for treatment of COVID-19 in Uganda
por: Trishul Siddharthan, et al.
Publicado: (2021-01-01)

Convalescent plasma appears efficacious and safe in COVID-19
por: Daulat Khulood, et al.
Publicado: (2020-09-01)

Management of COVID-19 Virus Infection by Convalescent Plasma
por: Abdol Majid Cheraghali, et al.
Publicado: (2020-05-01)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Daniele Focosi, et al.
Publicado: (2022-10-01)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: Gil C. De Santis, et al.
Publicado: (2022-05-01)

Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions
por: Tatiana Carvalho de Souza Bonetti, et al.
Publicado: (2021-08-01)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Harini Natarajan, et al.
Publicado: (2021-04-01)

Ebola Virus Antibodies in Fruit Bats, Bangladesh
por: Kevin J. Olival, et al.
Publicado: (2013-02-01)

Teaching research methodology within an Ebola virus outbreak.
por: Hope-Gill, B, et al.
Publicado: (2016)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Abhinay Gontu, et al.
Publicado: (2021-02-01)

Neutralizing antibodies in convalescent patients
por: Uhl, LFK, et al.
Publicado: (2020)

High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea
por: Philippine Eloy, et al.
Publicado: (2022-01-01)

Convalescent COVID-19 plasma
por: Vavić Nataša, et al.
Publicado: (2021-01-01)

Enfermedad por el virus del Ébola en el Centro de Tratamiento Coyah
por: Brigada médica cubana de lucha contra el Ébola en la República de Guinea
Publicado: (2017-09-01)

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
por: Livius Tirnea, et al.
Publicado: (2021-03-01)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Massimo Franchini, et al.
Publicado: (2021-09-01)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi Daniele, et al.
Publicado: (2021-01-01)

Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein
por: Rodriguez-Martinez, Luis Mario, et al.
Publicado: (2015)

THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF EBOLA VIRUS DISEASE
por: T. E. Sizikova, et al.
Publicado: (2018-12-01)

Ebola Virus Antibody Prevalence in Dogs and Human Risk
por: Loïs Allela, et al.
Publicado: (2005-03-01)

Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein.
por: Luis Mario Rodríguez-Martínez, et al.
Publicado: (2015-01-01)

What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea.
por: Maya Ronse, et al.
Publicado: (2018-10-01)

Prevalence of anti-HLA antibodies in COVID-19 convalescent plasma donors: an Indian experience
por: Ram Mohan Jaiswal, et al.
Publicado: (2024-10-01)

Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies
por: Katerina Jazbec, et al.
Publicado: (2023-03-01)

Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients
por: Ahmed S. Fahad, et al.
Publicado: (2021-02-01)

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
por: MEENU BAJPAI, et al.
Publicado: (2022-09-01)

Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
por: Hyung Park, et al.
Publicado: (2024-06-01)